<DOC>
	<DOCNO>NCT02658877</DOCNO>
	<brief_summary>The primary purpose study identify additional mechanism action omalizumab lead improve stratification patient treatment . Understanding response specific innate immune effector cell lung provide clues question . Investigators use non-invasive measure discrete cell population examine downstream effect omalizumab treatment lung . Information derive study help clarify mechanisms action omalizumab help identify potential tool patient endotyping stratification therapeutic intervention .</brief_summary>
	<brief_title>Sputum-derived Cellular Targets After Xolair ( Omalizumab )</brief_title>
	<detailed_description>This randomize , placebo-controlled , double blind , 16-week intervention study show feasibility proof concept . Analysis whole induce sputum development endotyping asthma , allow sample rare cell conduct airway , repeat sampling , cell-specific detailed genomic evaluation . Investigators develop novel technique simultaneously enrich innate immune cell sputum . This technique allow situ analysis sputum-derived human bronchial epithelial cell ( sHBEC ) . The non-invasive nature technique provide unique tool vivo human study .</detailed_description>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Physician diagnose asthma Lung function ( one follow document 5 year enrollment demonstration screen ) 1 . Bronchial hyper responsiveness ( BhR ) confirm ≥ 12 % improvement FEV1 post bronchodilator within previous 5 year , 2 . Methacholine PC20 &lt; 16mg/dl within previous 5 year Severity Criteria : Moderatepersistent asthma define American Thoracic Society ( ATS ) Asthma Control : Partly uncontrolled asthma accord GINA 2012 guideline ( least three follow feature : daytime symptom 2 times/week , limitation activity , nocturnal symptom , need rescue inhaler &gt; 2 times/week , FEV1 &lt; 80 % predict ) Stable use moderatehigh dose inhale corticosteroid previous 3 month ( definition derive GINA 2012 guideline : e.g . fluticasone propionate &gt; 250 mcg/day , budesonide &gt; 400mcg/day ) Ability perform induce sputum maneuver Presence elevate allergen IgE perennial aeroallergen Pulmonary function : FEV1 ≤ 70 % predict Any major chronic illness include limited Chronic Obstructive Pulmonary Disease ( COPD ) , uncontrolled hypertension , coronary artery disease , bronchiectasis , congestive heart failure , stroke , cystic fibrosis , insulindependent diabetes mellitus , renal failure , liver disorder , immunodeficiency state , condition would interfere participation study Current &gt; 10 pack year packyear tobacco use Any investigational study within previous 1 month Inability perform baseline measurement Inability contact telephone Pregnancy screening failure use double barrier pregnancy protection woman childbearing age Hypersensitivity reaction omalizumab past Exceeds limit dose table ( IgE &lt; 30 700 IU/ml ) body weight &lt; 30 &gt; 150kg Systemic corticosteroid within previous month Known malignant neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Xolair</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>asthma</keyword>
	<keyword>long-acting beta-agonists</keyword>
</DOC>